Trial Profile
A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NTB 011 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors NantBioScience
- 23 Aug 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 17 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.